Lab Interpretation
GI-MAP Dysbiosis Treatment: A Practitioner's Guide
Dysbiosis detected on GI-MAP doesn't have to feel like decoding a foreign language. Whether you're interpreting your own results or explaining them to...
GI-MAP dysbiosis means a stool PCR test found gut microbes or stool markers outside their expected ranges, such as low beneficial bacteria, higher opportunistic organisms or high beta-glucuronidase. The finding matters when the pattern fits the patient's symptoms, and this guide covers how to read that pattern, what stealth pathogens and beta-glucuronidase mean, and how clinicians frame treatment.
Part of the GI-MAP Interpretation Series: [[→ Pillar: GI-MAP Interpretation]] | [[→ Hub: Lab Interpretation]] | Work with a practitioner →
What is dysbiosis as shown on GI-MAP?
Dysbiosis refers to an imbalance in the gut microbiome, where beneficial and opportunistic microbes shift out of their usual ratio. On GI-MAP, this shows up as deviations from expected ranges across both commensal bacteria and opportunistic organisms.
GI-MAP uses qPCR DNA technology in place of traditional culture. It detects specific microbial DNA at the species and strain level and reports quantitative counts in addition to presence or absence.
On a GI-MAP report, dysbiosis typically appears as:
- Elevated opportunistic organisms (e.g., certain E. coli strains, Enterococcus, Klebsiella)
- Depleted beneficial bacteria (e.g., Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii)
- Abnormal commensal markers outside the lab's reference ranges
- Fungal findings (Candida spp., Saccharomyces cerevisiae)
The pattern matters more than any single number. A patient with low Lactobacillus but otherwise normal markers has a very different profile from someone with elevated Campylobacter and high Enterococcus at the same time. This is where clinical correlation earns its keep.
How do I interpret "stealth pathogens" on my GI-MAP?
"Stealth pathogens" is an informal clinical term for opportunistic microbes present at low levels without obvious acute illness. On GI-MAP, these often register at low quantities and may not line up with dramatic symptoms.
| Organism | Possible clinical significance |
|---|---|
| Campylobacter spp. | Low-grade inflammation, joint pain, fatigue |
| Yersinia enterocolitica | Digestive symptoms |
| Enterotoxigenic E. coli | Gas, bloating, immune activation |
| Helicobacter pylori | Gastric symptoms |
| Clostridioides difficile toxins | Needs prompt medical assessment if positive |
The useful clinical question is whether the organism is contributing to the patient's symptoms. A low-level finding in a patient without gut symptoms calls for more careful judgment than the same finding in a patient with chronic bloating, joint pain and fatigue. Whether to observe, retest or treat is a decision for the treating clinician.
What does beta-glucuronidase tell me about my gut?
Beta-glucuronidase is an enzyme made by certain gut bacteria that cleaves glucuronic acid conjugates in the intestinal lumen.
Why it matters: The liver attaches glucuronic acid to hormones (including estrogens) and other compounds so they can be excreted. Bacterial beta-glucuronidase can remove that tag in the gut, which may allow some of those compounds to be reabsorbed.
High beta-glucuronidase on GI-MAP is often discussed in relation to:
- Possible increased estrogen reabsorption
- Dysbiosis and higher opportunistic bacterial activity
- Low-fiber, Western-style diets
Low beta-glucuronidase may reflect reduced overall bacterial activity, for example after antibiotics.
A structural atlas of gut bacterial beta-glucuronidases found that these enzymes vary widely across bacterial species in structure and in which compounds they can process (Pollet et al., 2017, Structure; PMID: 28578872). Which bacteria are present shapes which glucuronides can be deconjugated.
Clinical framing: When beta-glucuronidase is high alongside dysbiosis, many clinicians focus on the underlying microbiome imbalance first.
How do clinicians approach GI-MAP dysbiosis?
Many functional medicine clinicians organize gut care with the 5R framework: Remove, Replace, Reinoculate, Repair and Rebalance. In broad terms:
- Remove: address organisms and dietary triggers that appear to be driving symptoms
- Replace: support digestion when markers suggest it is impaired
- Reinoculate: support beneficial bacteria, chosen to fit the test findings
- Repair: support the gut lining
- Rebalance: sleep, stress, diet and other lifestyle factors
The specific agents, doses, order and timing are individualized clinical decisions, and many clinicians retest to confirm progress. Findings such as positive occult blood, high calprotectin or C. difficile toxin need medical follow-up before any gut protocol.
How do I read GI-MAP results like a practitioner?
GI-MAP reports are organized into distinct sections:
Pathogens
- Bacterial, parasitic, viral and fungal organisms
- Any detection warrants correlation with the symptom picture
- → [[→ GI-MAP Pathogens Guide]] for species-specific interpretation
Commensals (beneficial bacteria)
- Lactobacillus, Bifidobacterium, Enterococcus, Faecalibacterium prausnitzii and others
- Low levels across several species suggest broader depletion
- → [[→ GI-MAP Commensals Guide]]
Immune markers
- Secretory IgA (sIgA): gut mucosal immune function
- Eosinophil Protein X: allergic and inflammatory activity
- → [[→ GI-MAP Immunity Markers]]
Digestion and absorption
- Pancreatic elastase-1 (exocrine pancreatic function)
- Fat malabsorption markers (steatocrit)
- → [[→ GI-MAP Digestion Markers]]
Special markers
- Beta-glucuronidase (see above)
- Occult blood: needs medical follow-up if positive
- Calprotectin: intestinal inflammation marker
Pattern-reading principle: Read markers together. High beta-glucuronidase plus depleted beneficial bacteria plus fat malabsorption tells a different story from any one of those findings alone.
Case example: putting it together
Patient: 34-year-old woman with chronic bloating, persistent fatigue and irregular bowel movements for 18 months. Prior workup unremarkable.
GI-MAP findings:
| Marker | Result |
|---|---|
| Beta-glucuronidase | High |
| Lactobacillus spp. | Low |
| Enterococcus spp. | Elevated |
| Campylobacter | Detected |
| Steatocrit (fat malabsorption) | Elevated |
| sIgA | Low-normal |
Interpretation: The pattern suggests dysbiosis with high beta-glucuronidase, impaired fat digestion that may add to bloating, and a low-level Campylobacter finding that may be sustaining inflammation. Low-normal sIgA hints at reduced mucosal immune function. Her clinician builds an individualized plan around these findings and retests to check progress. This is one illustrative case, and results vary.
Looking deeper
This article is part of the GI-MAP Interpretation Series:
- [[→ Pillar: GI-MAP Interpretation]]: complete test overview and clinical decision-making framework
- [[→ Hub: Lab Interpretation]]: all functional lab interpretation guides in one place
- [[→ GI-MAP Pathogens Guide]]: pathogen-specific detection
- [[→ GI-MAP Commensals Guide]]: beneficial bacteria
- [[→ GI-MAP Immunity Markers]]: sIgA, eosinophil protein X and mucosal immune health
- [[→ GI-MAP Digestion Markers]]: pancreatic elastase and fat malabsorption
References
- Pollet RM, D'Agostino EH, Walton WG, et al. "An Atlas of β-Glucuronidases in the Human Intestinal Microbiome." Structure. 2017;25(7):967-977.e5. PMID: 28578872
- Diagnostic Solutions Laboratory. GI-MAP Clinical Reference Guide. https://www.diagnosticsolutionslab.com/tests/gi-map
- Nordic Labs. GI-MAP Interpretive Guide. https://nordic-labs.com/ProductPDF/split_NL-GI%20MAP%20Guide-02_3827.pdf
Final thought
Dysbiosis on GI-MAP is a finding to interpret, and the quantitative results give you a baseline to measure against. The useful questions are whether the pattern explains the patient's symptoms and whether the plan is proportionate to the clinical picture.
Ready to understand your GI-MAP results?
Working with a practitioner who reads patterns, beyond single flagged markers, changes outcomes.
Book a GI-MAP Interpretation Consultation →
Already have results and want to go deeper? Explore the full GI-MAP series or learn how HANS, a clinical AI copilot that runs beside your EMR, helps functional medicine practitioners document and interpret complex labs faster →.
Want to learn more about gut health testing first? Start with our [[→ Pillar: GI-MAP Interpretation|complete GI-MAP test overview]].